Filing Flows › BioMarin Pharmaceutical (BMRN) › Q3 2026 › vs Q2 2026
BioMarin Pharmaceutical (BMRN) Q3 2026 vs Q2 2026 (quarter over quarter)
BioMarin Pharmaceutical's revenue rose $34.9M (+4%) from $990M in Q2 2026 to $1.0B in Q3 2026. The biggest changes: Net product revenues +$39.7M (+4%); Royalty and other revenues +$6.3M (+118%).
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 15.6% | 14.1% | +1.5 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| VOXZOGO | $245M | $253M | −$7.5M | -3% |
| VIMIZIM | $216M | $194M | $21.4M | +11% |
| GALAFOLD | $152M | $106M | $46.1M | +44% |
| PALYNZIQ | $111M | $135M | −$24.1M | -18% |
| NAGLAZYME | $108M | $135M | −$27.4M | -20% |
| ALDURAZYME | $56.6M | $43.5M | $13.1M | +30% |
| BRINEURA | $52.7M | $51.4M | $1.3M | +3% |
| POMBILITI + OPFOLDA | $48.6M | $30.3M | $18.3M | +61% |
| KUVAN | $22.9M | $24.4M | −$1.5M | -6% |
| Net product revenues | $1.0B | $973M | $39.7M | +4% |
| Royalty and other revenues | $11.6M | $5.3M | $6.3M | +118% |
| Revenue | $1.0B | $990M | $34.9M | +4% |
| Income tax benefit | $8.9M | −$16.6M | $25.6M | — |
| Net loss | $123M | −$44.8M | $168M | — |
| Costs & expenses | $1.2B | $990M | $167M | +17% |
| Operating costs | $1.1B | $879M | $228M | +26% |
| Interest & other, net | $49.7M | $49.5M | $152K | +0.3% |
| Cost of revenue | $205M | $203M | $2.6M | +1% |
| Research & development | $181M | $207M | −$26.4M | -13% |
| SG&A | $334M | $396M | −$61.9M | -16% |
| Other operating costs | $387M | $73.5M | $314M | +427% |
| Operating cash sources | $311M | $123M | $188M | +152% |
| Depreciation & amortization | $130M | $97.6M | $32.8M | +34% |
| Share-based compensation | $53.5M | $75.7M | −$22.2M | -29% |
| Working capital & other | $127M | −$50.0M | $177M | — |
| Net loss absorbed | $123M | −$44.8M | $168M | — |
| Operating cash flow | $188M | $168M | $20.1M | +12% |
| Free cash flow (OCF − capex) | $160M | $139M | $20.6M | +15% |
| Capital expenditures | $28.3M | $28.8M | −$523K | -2% |
Questions
How much did BioMarin Pharmaceutical's revenue grow quarter over quarter in Q3 2026?
BioMarin Pharmaceutical's revenue rose $34.9M (+4%) from $990M in Q2 2026 to $1.0B in Q3 2026.
What drove BioMarin Pharmaceutical's revenue change in Q3 2026?
Net product revenues +$39.7M (+4%); Royalty and other revenues +$6.3M (+118%).